## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0	287				
Estimated average	burden					
nours per response	e	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)													
1. Name and Address of Reporting Person * MCNAB JAMES R				2. Issuer Name and Ticker or Trading Symbol TITAN PHARMACEUTICALS INC [TTNP]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner					
310 BRC	) OAD STRE	(First) EET	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 01/28/2022					Office	er (give title belo	ow)	Other (specify	below)		
(Street) CHARLESTON, SC 29401			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(City		(State)	(Zip)		Ta	ble I - Nor	ı-Der	ivative S	Securities	Acqu	ired, Disp	osed of, or l	Beneficially	Owned	
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Ye			2A. Deemed Execution Date any (Month/Day/Ye	_	Code (Instr. 8)	4. Securities Acqui (A) or Disposed of (Instr. 3, 4 and 5)		of (D)	Beneficia	nt of Securities Illy Owned Following Transaction(s)		6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership		
				(monan bay) 1	<u> </u>	Code	V	Amoun	(A) or (D)	Price				or Indirect (I) (Instr. 4)	
Common	Stock		01/28/2022			J <u>(1)</u>		51,02	1 A	(1)	51,021	21		I	By JT Pharma
Common	Stock										1,669			D	
Reminder:	Report on a s	separate line for	each class of secur	ities beneficially	y ow	vned direct	ly or	indirectly	y						
							cont	ained ii	n this for	rm ar	e not requ	ction of inf uired to res OMB con	ormation spond unle trol numbe	ss	2 1474 (9-02)
				Derivative Secu e.g., puts, calls,		-		-			•				
1. Title of Derivative Security (Instr. 3)	ivative conversion or Exercise tr. 3) Price of Derivative Price of Derivative and Date (Month/Day/Year) Price of Derivative (Month/Day/Year) Price of Derivative (Month/Day/Year) Price of Derivative (Month/Day/Year) Price of Derivative Securities (Month/Day/Year)		7. T Am Und Sec	Title and ount of derlying urities str. 3 and		9. Number Derivative Securities Beneficiall Owned Following Reported Transaction (Instr. 4)	Owners Form of Derivat Securit Direct or India	Beneficia Ownershi y: (Instr. 4)							
				Code	V	(A) (D)	Date Exe		Expiration Date	n Titl	Amount or e Number of Shares				

### **Reporting Owners**

B 41 0 Y 4	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
MCNAB JAMES R 310 BROAD STREET CHARLESTON, SC 29401	X					

#### **Signatures**

/S/ James R. McNab	01/28/2022
**Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents \$50,000 of shares issued to JT Pharmaceuticals, Inc. ("JT") as a milestone payment under the October 2020 asset purchase agreement. Mr. McNab is a principal of JT and has voting and dispositive control of such shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.